FDA Adverse Event Injury Summary report: N

SPACEOAR SYSTEM

MDR report key: 6567901 · Received May 15, 2017

Report

Report Number
3008550999-2017-00002
Event Type
Injury
Date Received
May 15, 2017
Date of Event
April 12, 2017
Report Date
April 12, 2017
Manufacturer
AUGMENIX, INC
Product Code
OVB
UDI-DI
00864661000102
PMA / PMN Number
DEN140030
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
GA, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

AUGMENIX MEDICAL CONSULTANT REVIEWED MR IMAGES WITH COMPLAINANT PHYSICIAN ON APRIL 14, 2017. COMPLAINANT PHYSICIAN STATED PATIENT HAS A PRETTY HIGH RISK DISEASE. HE GOT A CS SEED IMPLANT WITH SPACEOAR PLACEMENT AT TIME OF IMPLANT FOUR WEEKS AGO. COMPLAINANT PHYSICIAN SAID IMAGING SHOWED GOOD SPACEOAR PLACEMENT AND RECTAL SEPARATION. NO PERINEAL PRESSURE OR PAIN BUT SUPER PAINFUL RECTAL EXAM AND VERY PAINFUL WITH EACH BOWEL TRANSIT. NO FEVERS OR ELEVATED WBC. TREATING PHYSICIAN STARTED HIM ON CIPRO AND FLAGYL. PATIENT IS SLIGHTLY GETTING BETTER BUT HE DOESN'T THINK ITS FROM ABX. GAS ON CBCT IS MAIN REASON HE IS THINKING INFECTION. IN FOLLOW-UP WITH COMPLAINANT PHYSICIAN, HE HAD INFORMED US THAT PATIENT PAIN HAS GOTTEN BETTER WITH ANTIBIOTICS. PATIENT HAD COMPLETED TREATMENT AND RETURNED TO WORK. AT LAST CBCT AIR WAS STILL PRESENT AND NOT OBVIOUSLY DIFFERENT. STERILIZATION RECORDS WERE REVIEWED AND WERE WITHIN SPECIFICATIONS. NO ADDITIONAL INFECTION COMPLAINTS WERE RECEIVED ASSOCIATED WITH THIS PRODUCTION LOT OF (B)(4) UNITS RELEASED FOR DISTRIBUTION AUGUST 19, 2016.

Description of Event or Problem · 1

COMPLAINANT PHYSICIAN NOTIFIED AUGMENIX, INC. THAT PATIENT WHO HAD A SPACE OAR AND SEED IMPLANT WAS EXPERIENCING RECTAL PAIN AND THERE IS ALSO UNUSUAL AIR IN SPACE. COMPLAINANT PHYSICIAN IS WORRIED ABOUT INFECTION AND WOULD LIKE TO SPEAK WITH SOMEONE ABOUT IT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
348724 SPACEOAR SYSTEM HYDROGEL SPACER OVB AUGMENIX, INC 11071601 00864661000102

Patients

Seq Age Sex Outcome Treatment
1 55 YR Required Intervention